We are committed to ensuring the continued supply of our medicines to patients in need.
• To date, we have had no disruptions and based on current inventory levels, we do not anticipate any shortage in the foreseeable future
• We are closely collaborating with our manufacturing partners across the world to implement strict prevention and response measures against COVID-19
• We have always maintained multi-source strategy to mitigate the risk of supply chain disruptions, and will continue to closely monitor inventory levels to accommodate market dynamics and fluctuations
Since the breakout of COVID-19, we have taken proactive measures to protect the health and well-being of our colleagues, families, and the community, and by extension the patients we serve.
To prevent the spread of COVID-19, we have ongoing disinfection of our facilities across the two campuses in South Korea. We have also implemented strict preventive measures such as health screening, restrictions on large in-person meetings and non-essential business travels, and limitations on external visitors to Samsung Bioepis sites.